Market Cap | 824.66M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -10.55M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 5.00% |
Sales | 245.32M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 5.00% |
Dividend | N/A | Price/Book | 4.03 | EPS next 5Y | - | 52W High Chg | -30.00% |
Recommedations | - | Quick Ratio | 3.28 | Shares Outstanding | 67.34M | 52W Low Chg | 45.00% |
Insider Own | - | ROA | -3.06% | Shares Float | 657.77M | Beta | 0.74 |
Inst Own | 0.07% | ROE | -4.98% | Shares Shorted/Prior | 1.32K/2.72K | Price | 12.50 |
Gross Margin | 89.72% | Profit Margin | -4.30% | Avg. Volume | 2,732 | Target Price | - |
Oper. Margin | -18.83% | Earnings Date | May 8 | Volume | 6 | Change | -1.96% |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
HC Wainwright & Co. | Buy | Mar 14, 24 |
HC Wainwright & Co. | Buy | Aug 3, 23 |
Oppenheimer | Outperform | Mar 28, 23 |
HC Wainwright & Co. | Buy | Mar 27, 23 |
HC Wainwright & Co. | Buy | Feb 22, 23 |
HC Wainwright & Co. | Buy | Feb 16, 23 |